MONITOR-HF试验:肺动脉压监测在慢性心衰临床相关亚组中的效应一致性
MONITOR-HF试验显示肺动脉压引导的心衰治疗优于标准治疗,可改善生活质量、减少心衰住院和平均肺动脉压。本亚组分析评估年龄、性别、房颤、糖尿病、左室射血分数、心衰病因、CRT和ICD等预设亚组,发现疗效在各亚组中一致,未观察到临床相关异质性,所有校正后交互作用P值均无统计学意义。
要点
- 肺动脉压引导治疗在慢性心衰各临床相关亚组中疗效一致
- 主要终点生活质量、临床事件和肺动脉压均未见显著异质性
- 未校正分析中老年和糖尿病患者交互作用趋势经多重检验校正后消失
核心结论
- 肺动脉压引导的心衰治疗在MONITOR-HF试验预设临床相关亚组中获益一致,支持其改善生活质量、临床事件和肺动脉压终点的疗效。
研究设计与样本
- MONITOR-HF试验的预设亚组分析,评估肺动脉压引导治疗在年龄、性别、房颤、糖尿病、左室射血分数、心衰病因、CRT和ICD等亚组中的效应一致性。
主要发现
- 肺动脉压监测对生活质量、临床事件和肺动脉压的效应在预设亚组中一致,所有终点类别内及类别间均无临床相关异质性,所有校正后交互作用P值均无统计学意义。
- 上述交互效应经多重检验校正后未持续存在。
临床怎么用
- 对于符合MONITOR-HF试验特征的慢性心衰患者,肺动脉压引导治疗可作为改善生活质量和减少心衰住院的选项,亚组间疗效一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated the efficacy of pulmonary artery (PA)-guided HF therapy over standard of care in improving quality of life and reducing HF hospitalizations and mean PA pressure. This study aimed to evaluate the consistency of these benefits in relation to clinically relevant subgroups. METHODS: The effect of PA-guided HF therapy was evaluated in the MONITOR-HF trial among predefined subgroups based on age, sex, atrial fibrillation, diabetes mellitus, left ventricular ejection fraction, HF aetiology, cardiac resynchronization therapy, and implantable cardioverter defibrillator. Outcome measures were based upon significance in the main trial and included quality of life-, clinical-, and PA pressure endpoints, and were assessed for each subgroup. Differential effects in relation to the subgroups were assessed with interaction terms. Both unadjusted and multiple testing adjusted interaction terms were presented. RESULTS: The effects of PA monitoring on quality of life, clinical events, and PA pressure were consistent in the predefined subgroups, without any clinically relevant heterogeneity within or across all endpoint categories (all adjusted interaction P-values were non-significant). In the unadjusted analysis of the primary endpoint quality-of-life change, weak trends towards a less pronounced effect in older patients (Pinteraction = .03; adjusted Pinteraction = .33) and diabetics (Pinteraction = .01; adjusted Pinteraction = .06) were observed. However, these interaction effects did not persist after adjusting for multiple testing. CONCLUSIONS: This subgroup analysis confirmed the consistent benefits of PA-guided HF therapy observed in the MONITOR-HF trial across clinically relevant subgroups, highlighting its efficacy in improving quality of life, clinical, and PA pressure endpoints in chronic HF patients.
引用
- Clephas PRD, Zwartkruis VW, Malgie J, et al. Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial. Eur Heart J. 2024. PMID: 38733175. doi:10.1093/eurheartj/ehae323
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。